Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market: By Therapy Type (Drug Therapy (Gemcitabine Combination Therapy, 5-fluorouracil Combination Therapy, Capecitabine Combination Therapy, and Gemcitabine Alone) Radiation Therapy (Brachytherapy and External Beam Radiation Therapy (EBRT), and Surgery), By Disease Indication (Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer and Distal Extrahepatic Bile Duct Cancer)), By Distribution Channel (Hospitals, Pharmacies, and Oncology Clinics), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Report Description:
Global bile duct cancer treatment market report gives comprehensive outlook on cholangiocarcinoma (bile duct cancer) therapies across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on cholangiocarcinoma (bile duct cancer) treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of therapy type, disease indication, and geographic regions. This report studies cholangiocarcinoma (bile duct cancer) treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, cholangiocarcinoma (bile duct cancer) treatment market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed cholangiocarcinoma (bile duct cancer) treatment market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Therapy Opportunities). Key stakeholders of the cholangiocarcinoma (bile duct cancer) treatment market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescription of cholangiocarcinoma (bile duct cancer) therapies.
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market:
Global cholangiocarcinoma (bile duct cancer) treatment market estimated to be valued US$ 184 Mn in 2017 and poised to grow at CAGR of 8.1% over 2017-2023. Market for cholangiocarcinoma (bile duct cancer) treatment projected to reach US$ 293 Mn by 2023 owing to growing prevalence of bile duct cancer and incidence of liver fluke infections in developing countries
Growing prevalence of liver and bile duct cancer in developed and developing markets driving market revenue growth
Market for bile duct cancer treatment is growing at healthy CAGR across the globe owing to rising incidence and prevalence of bile duct cancer across the globe. Moreover, the significant market growth has been observed in developing regions of Asia-pacific and Middle Eastern regions owing to common parasitic infection of the bile duct in these regions. For instance, according to The Cholangiocarcinoma Foundation, About 6,000 people in the United States develop bile duct cancer each year and Bile duct cancer is much more common in Asia and the Middle East, mostly because of a common parasitic infection of the bile duct.
Rising industrialization and orphan drug designation for bile duct cancer therapies likely impact market growth positively
The industrialization in developing counters such as India, china, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded with Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market. For instance, in 2017 RedHill Bio received orphan drug designation for YELIVA (ABC294640) in the treatment of cholangiocarcinoma.
Asia-Pacific emerged as prominent region for cholangiocarcinoma (bile duct cancer) treatment market across the globe
Asia-Pacific market is expected to hold the larger revenue share in global cholangiocarcinoma (bile duct cancer) treatment market and projected to remain dominant over the forecast period owing to growing prevalence and incidence of bile duct cancer in the region. North America cholangiocarcinoma (bile duct cancer) treatment market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to orphan designation status for drug molecules in the recent times for treating cholangiocarcinoma
COMPETITION ASSESSMENT
Key players profiles in the global Cholangiocarcinoma (Bile Duct Cancer) Treatment market include:
KEY FINDINGS OF THE REPORT:
By Therapy Type
Global bile duct cancer treatment market report gives comprehensive outlook on cholangiocarcinoma (bile duct cancer) therapies across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on cholangiocarcinoma (bile duct cancer) treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of therapy type, disease indication, and geographic regions. This report studies cholangiocarcinoma (bile duct cancer) treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, cholangiocarcinoma (bile duct cancer) treatment market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed cholangiocarcinoma (bile duct cancer) treatment market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Therapy Opportunities). Key stakeholders of the cholangiocarcinoma (bile duct cancer) treatment market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescription of cholangiocarcinoma (bile duct cancer) therapies.
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market:
Global cholangiocarcinoma (bile duct cancer) treatment market estimated to be valued US$ 184 Mn in 2017 and poised to grow at CAGR of 8.1% over 2017-2023. Market for cholangiocarcinoma (bile duct cancer) treatment projected to reach US$ 293 Mn by 2023 owing to growing prevalence of bile duct cancer and incidence of liver fluke infections in developing countries
Growing prevalence of liver and bile duct cancer in developed and developing markets driving market revenue growth
Market for bile duct cancer treatment is growing at healthy CAGR across the globe owing to rising incidence and prevalence of bile duct cancer across the globe. Moreover, the significant market growth has been observed in developing regions of Asia-pacific and Middle Eastern regions owing to common parasitic infection of the bile duct in these regions. For instance, according to The Cholangiocarcinoma Foundation, About 6,000 people in the United States develop bile duct cancer each year and Bile duct cancer is much more common in Asia and the Middle East, mostly because of a common parasitic infection of the bile duct.
Rising industrialization and orphan drug designation for bile duct cancer therapies likely impact market growth positively
The industrialization in developing counters such as India, china, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded with Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market. For instance, in 2017 RedHill Bio received orphan drug designation for YELIVA (ABC294640) in the treatment of cholangiocarcinoma.
Asia-Pacific emerged as prominent region for cholangiocarcinoma (bile duct cancer) treatment market across the globe
Asia-Pacific market is expected to hold the larger revenue share in global cholangiocarcinoma (bile duct cancer) treatment market and projected to remain dominant over the forecast period owing to growing prevalence and incidence of bile duct cancer in the region. North America cholangiocarcinoma (bile duct cancer) treatment market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to orphan designation status for drug molecules in the recent times for treating cholangiocarcinoma
COMPETITION ASSESSMENT
Key players profiles in the global Cholangiocarcinoma (Bile Duct Cancer) Treatment market include:
- Accord Healthcare Inc. (UK)
- Bristol-Myers Squibb Company (U.S)
- Celgene Corporation (U.S)
- Delcath Systems Inc. (U.S)
- Eli Lilly and Company. (U.S)
- F. Hoffman-La Roche AG (Switzerland)
- Fresenius Kabi AG (Germany)
- Johnson & Johnson Services Inc. (U.S)
- Kyowa Hakko Kirin Co Ltd. (Japan)
- Mylan N.V. (U.S)
- Novartis AG (Switzerland)
- Pfizer, Inc. (U.S)
- Sanofi (France)
- Teva Pharmaceuticals Industries Ltd. (Israel)
KEY FINDINGS OF THE REPORT:
- Global cholangiocarcinoma (bile duct cancer) treatment market expanding at 8.1 % CAGR over 2017 to 2023 to reach market value of US$ 293 Mn by 2023
- Based on treatment type, Gemcitabine Combination Therapy segment accounted for larger revenue share in 2016 owing to larger adoption in bile duct cancer treatment
- Extrahepatic bile duct cancer disease indication segment expected to hold larger revenue share in global market over the forecast period
- Hospital Pharmacies are prominent source for cholangiocarcinoma (bile duct cancer) therapies and accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
By Therapy Type
- Drug Therapy
- Gemcitabine Combination Therapy
- 5-fluorouracil Combination Therapy
- Capecitabine Combination Therapy
- Gemcitabine Alone
- Radiation Therapy
- Brachytherapy
- External Beam Radiation Therapy (EBRT)
- Surgery
- Intrahepatic Bile Duct Cancer
- Extrahepatic Bile Duct Cancer
- Perihilar Bile Duct Cancer
- Distal Extrahepatic Bile Duct Cancer
- Hospitals
- Pharmacies
- Oncology Clinics
- North America
- U.S
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
- Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
1. RESEARCH METHODOLOGY
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET DYNAMICS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET ANALYSIS, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Drug Therapy (Gemcitabine Combination Therapy, 5-fluorouracil Combination Therapy, Capecitabine Combination Therapy, Gemcitabine Alone)
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Radiation Therapy (Brachytherapy, External Beam Radiation Therapy (EBRT))
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Surgery
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET ANALYSIS, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Intrahepatic Bile Duct Cancer
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer, Distal Extrahepatic Bile Duct Cancer)
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospitals
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Drug Stores
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Oncology Centers
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.1.1. Drug Therapy
9.1.1.1.1. Gemcitabine Combination Therapy
9.1.1.1.2. 5-fluorouracil Combination Therapy
9.1.1.1.3. Capecitabine Combination Therapy
9.1.1.1.4. Gemcitabine Alone
9.1.1.2. Radiation Therapy
9.1.1.2.1. Brachytherapy
9.1.1.2.2. External Beam Radiation Therapy (EBRT)
9.1.1.3. Surgery
9.1.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.3. Intrahepatic Bile Duct Cancer
9.1.4. Extrahepatic Bile Duct Cancer
9.1.4.1. Perihilar Bile Duct Cancer
9.1.4.2. Distal Extrahepatic Bile Duct Cancer
9.1.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.5.1. Hospitals
9.1.5.2. Pharmacies
9.1.5.3. Oncology Centers
9.1.5.4. Drug Stores
9.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.6.1. U.S
9.1.6.2. Canada
9.2. Europe Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.2.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.1.1. Drug Therapy
9.2.1.1.1. Gemcitabine Combination Therapy
9.2.1.1.2. 5-fluorouracil Combination Therapy
9.2.1.1.3. Capecitabine Combination Therapy
9.2.1.1.4. Gemcitabine Alone
9.2.1.2. Radiation Therapy
9.2.1.2.1. Brachytherapy
9.2.1.2.2. External Beam Radiation Therapy (EBRT)
9.2.1.3. Surgery
9.2.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.3. Intrahepatic Bile Duct Cancer
9.2.4. Extrahepatic Bile Duct Cancer
9.2.4.1. Perihilar Bile Duct Cancer
9.2.4.2. Distal Extrahepatic Bile Duct Cancer
9.2.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.5.1. Hospitals
9.2.5.2. Pharmacies
9.2.5.3. Oncology Centers
9.2.5.4. Drug Stores
9.2.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.6.1. Germany
9.2.6.2. France
9.2.6.3. U.K
9.2.6.4. Italy
9.2.6.5. Spain
9.2.6.6. Russia
9.2.6.7. Poland 9.2.6.8. Rest of Europe
9.3. Asia-Pacific Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.3.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.1.1. Drug Therapy
9.3.1.1.1. Gemcitabine Combination Therapy
9.3.1.1.2. 5-fluorouracil Combination Therapy
9.3.1.1.3. Capecitabine Combination Therapy
9.3.1.1.4. Gemcitabine Alone
9.3.1.2. Radiation Therapy
9.3.1.2.1. Brachytherapy
9.3.1.2.2. External Beam Radiation Therapy (EBRT)
9.3.1.3. Surgery
9.3.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.3. Intrahepatic Bile Duct Cancer
9.3.4. Extrahepatic Bile Duct Cancer
9.3.4.1. Perihilar Bile Duct Cancer
9.3.4.2. Distal Extrahepatic Bile Duct Cancer
9.3.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.5.1. Hospitals
9.3.5.2. Pharmacies
9.3.5.3. Oncology Centers
9.3.5.4. Drug Stores
9.3.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.6.1. Japan
9.3.6.2. China
9.3.6.3. India
9.3.6.4. Australia & New Zealand 9.3.6.5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
9.3.6.6. South Korea
9.4. Latin America Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.4.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.1.1. Drug Therapy
9.4.1.1.1. Gemcitabine Combination Therapy
9.4.1.1.2. 5-fluorouracil Combination Therapy
9.4.1.1.3. Capecitabine Combination Therapy
9.4.1.1.4. Gemcitabine Alone
9.4.1.2. Radiation Therapy
9.4.1.2.1. Brachytherapy
9.4.1.2.2. External Beam Radiation Therapy (EBRT)
9.4.1.3. Surgery
9.4.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.3. Intrahepatic Bile Duct Cancer
9.4.4. Extrahepatic Bile Duct Cancer
9.4.4.1. Perihilar Bile Duct Cancer
9.4.4.2. Distal Extrahepatic Bile Duct Cancer
9.4.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.5.1. Hospitals
9.4.5.2. Pharmacies
9.4.5.3. Oncology Centers
9.4.5.4. Drug Stores
9.4.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.6.1. Brazil
9.4.6.2. Mexico
9.4.6.3. Argentina
9.4.6.4. Venezuela
9.4.6.5. Rest of Latin America
9.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.5.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.1.1. Drug Therapy
9.5.1.1.1. Gemcitabine Combination Therapy
9.5.1.1.2. 5-fluorouracil Combination Therapy
9.5.1.1.3. Capecitabine Combination Therapy
9.5.1.1.4. Gemcitabine Alone
9.5.1.2. Radiation Therapy
9.5.1.2.1. Brachytherapy
9.5.1.2.2. External Beam Radiation Therapy (EBRT)
9.5.1.3. Surgery
9.5.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.3. Intrahepatic Bile Duct Cancer
9.5.4. Extrahepatic Bile Duct Cancer
9.5.4.1. Perihilar Bile Duct Cancer
9.5.4.2. Distal Extrahepatic Bile Duct Cancer
9.5.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.5.1. Hospitals
9.5.5.2. Pharmacies
9.5.5.3. Oncology Centers
9.5.5.4. Drug Stores
9.5.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.6.1. Gulf Cooperation Council (GCC) Countries
9.5.6.2. Israel
9.5.6.3. South Africa
9.5.6.4. Rest of MEA
10. COMPETITION LANDSCAPE
10.1. Strategic Dashboard of Top Market Players
10.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
10.2.1. Accord Healthcare Inc. (UK)
10.2.2. Bristol-Myers Squibb Company (U.S)
10.2.3. Celgene Corporation (U.S)
10.2.4. Delcath Systems Inc. (U.S)
10.2.5. Eli Lilly and Company. (U.S)
10.2.6. F. Hoffman-La Roche AG (Switzerland)
10.2.7. Fresenius Kabi AG (Germany)
10.2.8. Johnson & Johnson Services Inc. (U.S)
10.2.9. Kyowa Hakko Kirin Co Ltd. (Japan)
10.2.10. Mylan N.V. (U.S)
10.2.11. Novartis AG (Switzerland)
10.2.12. Pfizer, Inc. (U.S)
10.2.13. Sanofi (France)
10.2. 14. Teva Pharmaceuticals Industries Ltd. (Israel)
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET DYNAMICS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET ANALYSIS, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Drug Therapy (Gemcitabine Combination Therapy, 5-fluorouracil Combination Therapy, Capecitabine Combination Therapy, Gemcitabine Alone)
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Radiation Therapy (Brachytherapy, External Beam Radiation Therapy (EBRT))
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Surgery
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET ANALYSIS, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Intrahepatic Bile Duct Cancer
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer, Distal Extrahepatic Bile Duct Cancer)
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospitals
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Drug Stores
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Oncology Centers
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL CHOLANGIOCARCINOMA (BILE DUCT CANCER) TREATMENT MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.1.1. Drug Therapy
9.1.1.1.1. Gemcitabine Combination Therapy
9.1.1.1.2. 5-fluorouracil Combination Therapy
9.1.1.1.3. Capecitabine Combination Therapy
9.1.1.1.4. Gemcitabine Alone
9.1.1.2. Radiation Therapy
9.1.1.2.1. Brachytherapy
9.1.1.2.2. External Beam Radiation Therapy (EBRT)
9.1.1.3. Surgery
9.1.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.3. Intrahepatic Bile Duct Cancer
9.1.4. Extrahepatic Bile Duct Cancer
9.1.4.1. Perihilar Bile Duct Cancer
9.1.4.2. Distal Extrahepatic Bile Duct Cancer
9.1.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.5.1. Hospitals
9.1.5.2. Pharmacies
9.1.5.3. Oncology Centers
9.1.5.4. Drug Stores
9.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.6.1. U.S
9.1.6.2. Canada
9.2. Europe Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.2.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.1.1. Drug Therapy
9.2.1.1.1. Gemcitabine Combination Therapy
9.2.1.1.2. 5-fluorouracil Combination Therapy
9.2.1.1.3. Capecitabine Combination Therapy
9.2.1.1.4. Gemcitabine Alone
9.2.1.2. Radiation Therapy
9.2.1.2.1. Brachytherapy
9.2.1.2.2. External Beam Radiation Therapy (EBRT)
9.2.1.3. Surgery
9.2.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.3. Intrahepatic Bile Duct Cancer
9.2.4. Extrahepatic Bile Duct Cancer
9.2.4.1. Perihilar Bile Duct Cancer
9.2.4.2. Distal Extrahepatic Bile Duct Cancer
9.2.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.5.1. Hospitals
9.2.5.2. Pharmacies
9.2.5.3. Oncology Centers
9.2.5.4. Drug Stores
9.2.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.6.1. Germany
9.2.6.2. France
9.2.6.3. U.K
9.2.6.4. Italy
9.2.6.5. Spain
9.2.6.6. Russia
9.2.6.7. Poland 9.2.6.8. Rest of Europe
9.3. Asia-Pacific Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.3.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.1.1. Drug Therapy
9.3.1.1.1. Gemcitabine Combination Therapy
9.3.1.1.2. 5-fluorouracil Combination Therapy
9.3.1.1.3. Capecitabine Combination Therapy
9.3.1.1.4. Gemcitabine Alone
9.3.1.2. Radiation Therapy
9.3.1.2.1. Brachytherapy
9.3.1.2.2. External Beam Radiation Therapy (EBRT)
9.3.1.3. Surgery
9.3.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.3. Intrahepatic Bile Duct Cancer
9.3.4. Extrahepatic Bile Duct Cancer
9.3.4.1. Perihilar Bile Duct Cancer
9.3.4.2. Distal Extrahepatic Bile Duct Cancer
9.3.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.5.1. Hospitals
9.3.5.2. Pharmacies
9.3.5.3. Oncology Centers
9.3.5.4. Drug Stores
9.3.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.6.1. Japan
9.3.6.2. China
9.3.6.3. India
9.3.6.4. Australia & New Zealand 9.3.6.5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
9.3.6.6. South Korea
9.4. Latin America Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.4.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.1.1. Drug Therapy
9.4.1.1.1. Gemcitabine Combination Therapy
9.4.1.1.2. 5-fluorouracil Combination Therapy
9.4.1.1.3. Capecitabine Combination Therapy
9.4.1.1.4. Gemcitabine Alone
9.4.1.2. Radiation Therapy
9.4.1.2.1. Brachytherapy
9.4.1.2.2. External Beam Radiation Therapy (EBRT)
9.4.1.3. Surgery
9.4.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.3. Intrahepatic Bile Duct Cancer
9.4.4. Extrahepatic Bile Duct Cancer
9.4.4.1. Perihilar Bile Duct Cancer
9.4.4.2. Distal Extrahepatic Bile Duct Cancer
9.4.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.5.1. Hospitals
9.4.5.2. Pharmacies
9.4.5.3. Oncology Centers
9.4.5.4. Drug Stores
9.4.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.6.1. Brazil
9.4.6.2. Mexico
9.4.6.3. Argentina
9.4.6.4. Venezuela
9.4.6.5. Rest of Latin America
9.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.5.1. Therapy Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.1.1. Drug Therapy
9.5.1.1.1. Gemcitabine Combination Therapy
9.5.1.1.2. 5-fluorouracil Combination Therapy
9.5.1.1.3. Capecitabine Combination Therapy
9.5.1.1.4. Gemcitabine Alone
9.5.1.2. Radiation Therapy
9.5.1.2.1. Brachytherapy
9.5.1.2.2. External Beam Radiation Therapy (EBRT)
9.5.1.3. Surgery
9.5.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.3. Intrahepatic Bile Duct Cancer
9.5.4. Extrahepatic Bile Duct Cancer
9.5.4.1. Perihilar Bile Duct Cancer
9.5.4.2. Distal Extrahepatic Bile Duct Cancer
9.5.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.5.1. Hospitals
9.5.5.2. Pharmacies
9.5.5.3. Oncology Centers
9.5.5.4. Drug Stores
9.5.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.6.1. Gulf Cooperation Council (GCC) Countries
9.5.6.2. Israel
9.5.6.3. South Africa
9.5.6.4. Rest of MEA
10. COMPETITION LANDSCAPE
10.1. Strategic Dashboard of Top Market Players
10.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
10.2.1. Accord Healthcare Inc. (UK)
10.2.2. Bristol-Myers Squibb Company (U.S)
10.2.3. Celgene Corporation (U.S)
10.2.4. Delcath Systems Inc. (U.S)
10.2.5. Eli Lilly and Company. (U.S)
10.2.6. F. Hoffman-La Roche AG (Switzerland)
10.2.7. Fresenius Kabi AG (Germany)
10.2.8. Johnson & Johnson Services Inc. (U.S)
10.2.9. Kyowa Hakko Kirin Co Ltd. (Japan)
10.2.10. Mylan N.V. (U.S)
10.2.11. Novartis AG (Switzerland)
10.2.12. Pfizer, Inc. (U.S)
10.2.13. Sanofi (France)
10.2. 14. Teva Pharmaceuticals Industries Ltd. (Israel)
